Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
8.10
+0.17 (2.14%)
Jan 22, 2026, 4:00 PM EST - Market closed
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 368 employees as of December 31, 2024. The number of employees increased by 165 or 81.28% compared to the previous year.
Employees
368
Change (1Y)
165
Growth (1Y)
81.28%
Revenue / Employee
$576,288
Profits / Employee
-$228,802
Market Cap
478.68M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 368 | 165 | 81.28% |
| Dec 31, 2023 | 203 | -87 | -30.00% |
| Dec 31, 2022 | 290 | 12 | 4.32% |
| Dec 31, 2021 | 278 | -14 | -4.79% |
| Dec 31, 2020 | 292 | 8 | 2.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 305 |
| ADC Therapeutics | 265 |
| 4D Molecular Therapeutics | 227 |
| Absci | 157 |
| Niagen Bioscience | 104 |
| Aclaris Therapeutics | 64 |
| Contineum Therapeutics | 41 |
| Anavex Life Sciences | 34 |
VNDA News
- 7 days ago - Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Vanda and Exante Data Combine in Strategic Merger - Business Wire
- 14 days ago - Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder - PRNewsWire
- 21 days ago - Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus - Seeking Alpha
- 22 days ago - Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval - Barrons
- 23 days ago - US FDA approves Vanda Pharmaceuticals' motion sickness drug - Reuters
- 23 days ago - Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PRNewsWire
- 5 weeks ago - Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire